Michael Drummond
Professor

Profile

Biography

Mike is Professor of Health Economics and was Director of the Centre from December 1995 to September 2005. His particular field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunisation programmes, services for people with AIDS, eye health care and pharmaceuticals.

He is the author of two major textbooks and more than 700 scientific papers, has acted as a consultant to the World Health Organization and was Project Leader of a European Union Project on the Methodology of Economic Appraisal of Health Technology. He has also served on the Boards of Directors of the International Society of Technology Assessment in Health Care and the International Society for Pharmacoeconomics and Outcomes Research. He has been President of the International Society for Pharmacoeconomics and Outcomes Research.  He is currently Co-Editor-in-Chief of Value in Health. 

Professor Drummond has been awarded three honorary degrees, from City University, London (2008), Erasmus University, Rotterdam (2012) and the University of Lisbon (2015). In 2010 he was made a member of the Institute of Medicine of the National Academies in the USA, being one of only 27 members from the UK. 

Mike Drummond was the recipient of the Avedis Donabedian Award in recognition of lifetime achievement in the area of improving health outcomes (2004) and the John Eisenberg Award, in recognition of exemplary leadership in the practical application of medical decision-making research (2012).

His recent projects relate to the conduct of economic evaluations and their use in health care decision making. 

Research

Overview

Mike's recent projects relate to the conduct of economic evaluations and their use in health care decision making. These include:

• NHS Economic Evaluation Database (funded by NHS R&D)
• Assessment of the socio-economic value of medical devices (funded by the European Health Technology Institute)

Research group(s)

• Economic evaluation of health technologies

External activities

Invited talks and conferences

2012

• Drummond M. Assessing the added value of health technologies: reconciling different perspectives. EABIS Conference, Sustaining and Implementing Universal Health Coverage: 4 Perspectives for 5 Continents, Milan, February 2012.
• Drummond M. Value based pricing for pharmaceuticals. Economic Research Council, London, April 2012.
• Drummond M. Roles as a moderator, panellist, discussion leader, and presenter at the 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research held in Washington DC, June 2012.

2011

• Despiégel N, Danchenko N, François C, Lensberg B, Drummond M. The use and performance of productivity scales to evaluate presenteeism in mood disorders. ISPOR 14th Annual European Congress, Madrid, 5-8 Nov 2011.
• Drummond M. Twenty years of using economic evaluations for drug reimbursement decisions. What have we achieved? 33rd Australian Conference of Health Economists, Melbourne, Sept 2011.
• Drummond M. Economic analysis in NICE clinical guidelines in the United Kingdom. International Health Economics Association (iHEA), Toronto, July 2011.
• Drummond M. Restricting access to healthcare: is NICE too nasty?  Presentation to the Public Health Economics Group, John Hopkins University, Baltimore, May 2011.

2010

• Drummond M. Key trends and developments in HTA in Europe: searching for value. ISPOR 13th Annual European Congress, Prague, 6-8 Nov 2010.
• Drummond M. Pharmacoeconomics as a discipline: past, present and future. College of Pharmacy, University of New Mexico, Oct 2010.
• Drummond M. Putting some flesh on the bones of economic evaluation in osteoarthritis. University of Calgary, Canada, 27 Sept 2010.
• Drummond M. The societal perspective in the evaluation of public health programmes. 8th European Conference on Health Economics, Helsinki, July 2010.
• Drummond M. On the economic value of orphan drugs. 8th European Conference on Health Economics, Helsinki, July 2010.
• Drummond M. Are orphan drugs a special case? 8th European Conference on Health Economics, Helsinki, July 2010.
• Drummond M. The rise of technology evaluation in health economics.  Plenary presentation, Collège des Economistes de la Santé Conference, Paris, 19 March 2010.
• Drummond M. The NICE approach to the clinical and cost-effectiveness of healthcare interventions. Presentation at a National Institutes of Health Workshop on the Economics of Nutritional Interventions in Washington DC, Feb 2010.
• Drummond M. NICEly does it: recent developments in the use of HTA in the United Kingdom. Presentation at a Health Policy Seminar,  Tufts Medical Center, Tufts University, Boston, Feb 2010.